Moderna Delays Bid for Covid Shot Patent Disputed by NIH
- NIH has said its researchers deserve credit for Covid shot
- Moderna said it’s negotiating over list of inventors
This article is for subscribers only.
We're tracking the latest on the coronavirus outbreak and the global response. Sign up here for our daily newsletter on what you need to know.
Moderna Inc. said it has delayed efforts to obtain a patent on its Covid vaccine that’s in dispute with the U.S. government over who should be listed as inventors, allowing more time for negotiations.